| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.12美元,归母净利润470.00万美元,同比去年增长242.32%
|
| 2025-11-11 |
财报披露：
美东时间 2025-11-11 盘前发布财报
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益0.08美元,归母净利润313.40万美元,同比去年增长340.79%
|
| 2025-08-06 |
股东大会：
将于2025-09-11召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2025 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2024;
2.To approve the re-election of each of Mr. Ami Boehm (Chairman), Dr. David Zacut (Vice Chairman), Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Avner Lushi and Mr. Jonathan Shulkin as directors to the Board of Directors of the Company;
3.To approve the update in compensation and the grant of equity in the form of restricted share units to Mr. Hadar Levy, the Company’s Chief Executive Officer.
|
| 2025-08-06 |
股东大会：
将于2025-09-11召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2025 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2024;
2.To approve the re-election of each of Mr. Ami Boehm (Chairman), Dr. David Zacut (Vice Chairman), Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Avner Lushi and Mr. Jonathan Shulkin as directors to the Board of Directors of the Company;
3.To approve the update in compensation and the grant of equity in the form of restricted share units to Mr. Hadar Levy, the Company’s Chief Executive Officer.
|
| 2025-08-06 |
详情>>
股本变动：
变动后总股本1890.18万股
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益0.03美元,归母净利润110.70万美元,同比去年增长897.30%
|
| 2025-04-22 |
详情>>
业绩披露：
2022年年报每股收益-0.4美元,归母净利润-1334.9万美元,同比去年增长-106.58%
|
| 2025-04-22 |
详情>>
业绩披露：
2024年年报每股收益0.09美元,归母净利润292.10万美元,同比去年增长169.60%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.04美元,归母净利润137.30万美元,同比去年增长131.75%
|
| 2024-10-01 |
股东大会：
将于2024-11-05召开股东大会
会议内容 ▼▲
- 1.To approve certain matters to be effected in connection with the Securities Purchase Agreement with Valor BrainsWay Holdings, LLC (“Valor”), dated as of September 29, 2024, as further detailed in this Proxy Statement: (i) the issuance of 2,103,745 American Depository Shares (“ADSs”), with each ADS representing 2 Ordinary Shares (as defined below) of the Company, and the issuance of a warrant to purchase an additional 1,500,000 ADSs, with each ADS representing 2 Ordinary Shares of the Company, to Valor under the Valor Transaction (as defined below); (ii) to approve an amendment to the Articles of Association of the Company granting Valor the right to designate director(s) to the Board of Directors of the Company; and (iii) to approve the appointment of Mr. Jonathan Shulkin as a member of the Board of Directors of the Company.
2.To act upon any other matters that may properly come before the Extraordinary Meeting or any adjournment or postponement thereof.
|
| 2024-10-01 |
股东大会：
将于2024-11-05召开股东大会
会议内容 ▼▲
- 1.To approve certain matters to be effected in connection with the Securities Purchase Agreement with Valor BrainsWay Holdings, LLC (“Valor”), dated as of September 29, 2024, as further detailed in this Proxy Statement: (i) the issuance of 2,103,745 American Depository Shares (“ADSs”), with each ADS representing 2 Ordinary Shares (as defined below) of the Company, and the issuance of a warrant to purchase an additional 1,500,000 ADSs, with each ADS representing 2 Ordinary Shares of the Company, to Valor under the Valor Transaction (as defined below); (ii) to approve an amendment to the Articles of Association of the Company granting Valor the right to designate director(s) to the Board of Directors of the Company; and (iii) to approve the appointment of Mr. Jonathan Shulkin as a member of the Board of Directors of the Company.
2.To act upon any other matters that may properly come before the Extraordinary Meeting or any adjournment or postponement thereof.
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益0.02美元,归母净利润71.10万美元,同比去年增长117.37%
|
| 2024-05-09 |
股东大会：
将于2024-06-17召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2024 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2023.
2.To approve the re-election of each of Mr. Ami Boehm (Chairman), Dr. David Zacut, Mr. Avner Hagai, Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the Board of Directors of the Company.
3.To approve compensation and grant of equity in the form of options and restricted share units for Ami Boehm for his role as the chairman of the Board of Directors.
4.To approve the grant of equity including options and restricted share units to the directors of the Company.
5.To approve the grant of equity including options and restricted share units to Mr. Hadar Levy, the Company’s Chief Executive Officer of the Company.
6.To approve the Compensation Policy of the Company.
|
| 2024-05-09 |
股东大会：
将于2024-06-17召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2024 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2023.
2.To approve the re-election of each of Mr. Ami Boehm (Chairman), Dr. David Zacut, Mr. Avner Hagai, Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the Board of Directors of the Company.
3.To approve compensation and grant of equity in the form of options and restricted share units for Ami Boehm for his role as the chairman of the Board of Directors.
4.To approve the grant of equity including options and restricted share units to the directors of the Company.
5.To approve the grant of equity including options and restricted share units to Mr. Hadar Levy, the Company’s Chief Executive Officer of the Company.
6.To approve the Compensation Policy of the Company.
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益0.00美元,归母净利润11.10万美元,同比去年增长104.57%
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-0.13美元,归母净利润-419.7万美元,同比去年增长68.56%
|
| 2023-11-15 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.13美元,归母净利润-432.4万美元,同比去年增长54.40%
|
| 2023-02-13 |
股东大会：
将于2023-03-20召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2022 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2021.
2.To approve the election of Mr. Ami Boehm as a director to the Board of Directors of the Company, and the re-election of each of Dr. David Zacut, Mr. Avner Hagai, Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the board of directors of the Company.
3.To approve compensation for Ami Boehm for his role as the Chairman of the Board of Directors.
4.To approve compensation for Dr. David Zacut for his role as a special consultant of the Company.
5.To approve compensation for Hadar Levy, the Company's Chief Executive Officer.
6.To approve an amendment to the Compensation Policy of the Company.
|
| 2023-02-13 |
股东大会：
将于2023-03-20召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2022 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2021.
2.To approve the election of Mr. Ami Boehm as a director to the Board of Directors of the Company, and the re-election of each of Dr. David Zacut, Mr. Avner Hagai, Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Avraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the board of directors of the Company.
3.To approve compensation for Ami Boehm for his role as the Chairman of the Board of Directors.
4.To approve compensation for Dr. David Zacut for his role as a special consultant of the Company.
5.To approve compensation for Hadar Levy, the Company's Chief Executive Officer.
6.To approve an amendment to the Compensation Policy of the Company.
|
| 2021-11-17 |
股东大会：
将于2021-12-22召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2021 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2020;
2.To approve the Company's Amended and Restated Compensation Policy;
3.To approve the re-election of Dr. David Zacut as Chairman of the Board of Directors of the Company, Mr. Avner Hagai as Vice Chairman of the Board of Directors of the Company, and Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Abraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the board of directors of the Company;
4.To approve an increase in the Company’s authorized share capital by 60,000,000 ordinary shares, par value NIS 0.04 per share from 60,000,000 ordinary shares, par value NIS 0.04 per share to 120,000,000 ordinary shares, par value NIS 0.04 per share, and to amend the Articles of Association of the Company accordingly.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-02-23 |
复牌提示：
2021-02-22 16:00:14 停牌，复牌日期 2021-02-23 09:15:00
|
| 2021-01-27 |
股东大会：
将于2021-03-04召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2020 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2019;
2.To approve the re-election of Dr. David Zacut as Chairman of the Board of Directors of the Company, Mr. Avner Hagai as Vice Chairman of the Board of Directors of the Company, and Ms. Eti Mitrany, Ms. Karen Sarid, Prof. Abraham Zangen, Mr. Yossi Ben Shalom and Mr. Avner Lushi as directors to the board of directors of the Company;
3.To approve the repricing of the independent directors' existing options to an exercise price equal to the higher of (a) $4.675 ($9.35 per ADS) being a price equal to the closing price per Ordinary Share on January 25th, 2021 and, (b) the closing price per Ordinary Share on the last trading date before the date of approval by the shareholders of this proposal;
4.To approve the grant on the date of this resolution of 180,000 RSUs to Christopher von Jako, President and Chief Executive Officer of the Company, subject to a 4-year vesting schedule, in lieu of three separate previously committed annual grants of 60,000 RSUs that would have been granted on each of March 31st 2021, March 31st 2022 and March 31st 2023 subject to certain criteria specified in his employment agreement;
5.To approve an increase in the Company’s authorized share capital by 25,000,000 ordinary shares, par value NIS 0.04 per share from 35,000,000 ordinary shares, par value NIS 0.04 per share to 60,000,000 ordinary shares, par value NIS 0.04 per share, and to amend the Articles of Association of the Company accordingly.
|
| 2019-12-09 |
股东大会：
将于2020-01-13召开股东大会
会议内容 ▼▲
- 1.To appoint Kost Forer Gabbay & Kasierer, certified public accountants in Israel and a member of Ernst & Young Global, as the Company’s independent auditors for the year 2019 and for an additional period until the following annual general meeting and to authorize the Board of Directors to determine their compensation for the year; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2018;
2.To approve the re-election of Dr. David Zacut and Mr. Avner Hagai and the election of Mr. Avner Lushi as directors to the board of directors of the Company;
3.To approve the grant of options to the directors Ms. Eti Mitrany and Mr. Avner Lushi;
4.To approve amendments to the Company's compensation policy;
5.To approve compensation for Christopher R. von Jako, Ph.D., the Company's future president and chief executive officer;
6.To approve compensation for Dr. David Zacut for his role as the chairman of the Board of Directors;
7.To approve compensation for Dr. David Zacut for the 3 month on-the-job-training to Company's entering president and chief executive officer;
8.To approve amendments to the Company's Articles of Association.
|
| 2019-10-11 |
股东大会：
将于2019-11-25召开股东大会
会议内容 ▼▲
- 1.To approve the engagement by the Company of Dr. David Zacut, the Company's Chairman of the Board of Directors, as the Company's interim Chief Executive Officer for a term of up to one year, and the increase of the capacity of his consultancy to the Company accordingly;
2.To approve an amendment to the Company's Articles of Association relating to the office of directors appointed by the Board of Directors of the Company;
3.To approve an amendment to the Company's Articles of Association to change the shareholders' majority required for amending articles relating to the Board of Directors of the Company and for removing a director from his/her position;
4.To approve the Brainsway Ltd. Amended and Restated 2019 Share Incentive Plan.
|